Starting on:
Sep 5, 2024
Ending on:
Sep 5, 2024
Moderator(s):
Go to activity
Max Credits:
2 Points
Provider:
International Cancer Institute
Claim Points
Sep 5, 2024
Ending on:
Sep 5, 2024
Moderator(s):
Prof.
Florian Lordick
Florian Lordick is a Full Professor of Medicine at the University of Leipzig, Germany. He was appointed as director of the University Cancer Center Leipzig in 2012, which, in collaboration with the University of Jena Medical Center, recently was awarded as one of 15 German Oncology Centers of Excellence and receives funding from the German Cancer Aid. He also is head of the Department of Medicine (oncology, gastroenterology, hepatology, and pulmonology) at the University of Leipzig Medical Center. Dr. Lordick’s scientific focus is on clinical and translational research in immuno- oncology and targeted treatment of cancer, with a specific focus on gastrointestinal tract tumours. He has a great interest in multimodality treatment of GI cancers, in personalized medicine and in survivorship topics. His research is funded by the German Cancer Aid, the German Ministry of Education and Research and by the European Commission. Dr. Lordick has authored and co-authored more than 400 peer-reviewed and PubMed-listed articles. Dr. Lordick served as Director of Education at the European Society for Medical Oncology (ESMO) from 2019-2022, as president of the International Gastric Cancer Association (IGCA) and he is a former member of the executive board of the German Cancer Society and former chair of the EORTC Gastrointestinal Tract Cancer Working groups. He holds reviewer and advisory roles at various research funding organizations and European comprehensive cancer centers. He also is the newly appointed Editor-in- Chief of ESMO Gastrointestinal Oncology, official scientific journal of the European Society for Medical Oncology.
URL: Florian Lordick is a Full Professor of Medicine at the University of Leipzig, Germany. He was appointed as director of the University Cancer Center Leipzig in 2012, which, in collaboration with the University of Jena Medical Center, recently was awarded as one of 15 German Oncology Centers of Excellence and receives funding from the German Cancer Aid. He also is head of the Department of Medicine (oncology, gastroenterology, hepatology, and pulmonology) at the University of Leipzig Medical Center. Dr. Lordick’s scientific focus is on clinical and translational research in immuno- oncology and targeted treatment of cancer, with a specific focus on gastrointestinal tract tumours. He has a great interest in multimodality treatment of GI cancers, in personalized medicine and in survivorship topics. His research is funded by the German Cancer Aid, the German Ministry of Education and Research and by the European Commission. Dr. Lordick has authored and co-authored more than 400 peer-reviewed and PubMed-listed articles. Dr. Lordick served as Director of Education at the European Society for Medical Oncology (ESMO) from 2019-2022, as president of the International Gastric Cancer Association (IGCA) and he is a former member of the executive board of the German Cancer Society and former chair of the EORTC Gastrointestinal Tract Cancer Working groups. He holds reviewer and advisory roles at various research funding organizations and European comprehensive cancer centers. He also is the newly appointed Editor-in- Chief of ESMO Gastrointestinal Oncology, official scientific journal of the European Society for Medical Oncology.
Go to activity
Max Credits:
2 Points
Provider:
International Cancer Institute
Claim Points
Inaugural Virtual Multidisciplinary Tumor Board: ICI and AFROC: 2 Cases on To CROSS or not: a Case Study of Neoadjuvant CCRT for Oesophageal Cancer and Treatment of locally advanced/oligometastatic squamous cell carcinoma of the esophagus
Starting on:
Sep 5, 2024
Sep 5, 2024
Ending on:
Sep 5, 2024
Sep 5, 2024
Venue:
Description
International Cancer Institute invites you to attend the Virtual Multidisciplinary Tumor Board case presentation on solid cancers and hematological malignancies, followed by an expert discussion on patient Management. The multidisciplinary team will review recent advancements in oncology, cancer patients’ safety and health outcomes, interdisciplinary collaboration, and treatment plans. There will be a Q&A session with an open floor for insights.
Objectives
To understand the management of various solid cancers and hematological malignancies
To understand the importance of integrating palliative and survivorship care in cancer management
To understand the importance of a multidisciplinary team approach in cancer management
Presenters
-
Dr.
Muhammed Bapeekee
Dr Muhammed Ahmed Sadeck Bapeekee Muhammed Bapeekee is a Consultant Radiation Oncologist currently practicing at the University of the Witwatersrand and Charlotte Maxeke Johannesburg Academic Hospital. He runs the GIT, skin and urology oncology firms at the hospital. He is involved in the academic program of training residents for the Fellowship in Radiation Oncology at the College of Medicine South Africa. His interests include GIT malignancies including oesophageal, rectal and anal cancer. He is currently completing his Master of Medicine (Mmed) thesis which is looking at the role of FDG PET/CT in staging oesophageal cancer in the South African setting.
University of the Witwatersrand and Charlotte Maxeke Johannesburg Academic Hospital -
Prof.
Radka Obermannova,
Dr. Radka Obermannova, Ph.D., is a Consultant Medical Oncologist at the Department of Comprehensive Cancer Care at Masaryk Memorial Cancer Institute in Brno, Czech Republic. She is specialized in the treatment of patients with gastrointestinal cancers. She graduated from Masaryk University in Brno and completed her Medical Oncology training and Ph.D. study at the same university. Her scientific focus on GI cancer inspired her for a subsequent research career, namely in her interest in optimizing multimodal gastric cancer treatment involving predictors of treatment response. Dr. Obermannova was GI inpatient ward head physician and since 2012 serves as a chief physician of a Phase I Unit. She is involved in drug development as a principal investigator and co-investigator of phase I-III clinical trials. Dr. Obermannova is a co- author of national guidelines on oesophageal and gastric cancer, and she is also co- author of ESMO oesophageal cancer treatment guidelines. Dr. Obermannova is an active member of the ESMO Gastrointestinal Non-Colorectal Faculty Group and co-Chair of the EORTC Individualized therapy Task Force at the Gastrointestinal Tract Cancer Working Group. She is also a member of the International Gastric Cancer Association (IGCA) and the Czech Society for Oncology.
Masaryk Memorial Cancer Institute in Brno, Czech Republic.